Jansen N Seheult1, Marshall Bahr2, Vincent Anto3, Louis H Alarcon4,5, Alain Corcos4,5, Jason L Sperry4,5, Darrell J Triulzi1,6, Mark H Yazer1,6. 1. Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Department of Anesthesiology, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 4. Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. The Institute for Transfusion Medicine, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: The use of cold-stored low-titer group O whole blood (LTOWB) for civilian trauma patients is gaining popularity. However, hemolysis might occur among non-group O recipients. This study evaluated the serologic safety of transfusing up to 4 units of LTOWB. STUDY DESIGN AND METHODS: Hypotensive male and at least 50-year-old female trauma patients who received leukoreduced, uncrossmatched, group O+, low-titer (<50 anti-A and anti-B), platelet-replete whole blood during initial resuscitation were included in this prospective, observational study. Biochemical markers of hemolysis were measured on the day of LTOWB receipt (Day 0) and over the next 2 days. Blood product administration in the first 24 hours of admission and reported transfusion-associated adverse events were also reviewed. RESULTS: There were 102 non-group O and 70 group O recipients of 1 to 4 LTOWB units analyzed. The non-group O recipients received a median volume of 600 mL (range, 300-4100 mL) of ABO-incompatible plasma, including the contribution from the LTOWB units. There were no significant differences in median haptoglobin, lactate dehydrogenase, total bilirubin, creatinine, or potassium levels at any time point between the non-group O and group O recipients. There were also no differences in these markers between the subset of 23 non-group O and 14 group O recipients who received 3 or 4 LTOWB units. No transfusion-associated adverse events were reported. CONCLUSIONS: Administration of up to 4 units of LTOWB in civilian trauma resuscitation was not associated with clinical or biochemical evidence of hemolysis. Six units per trauma patient are now permitted at these institutions.
BACKGROUND: The use of cold-stored low-titer group O whole blood (LTOWB) for civilian traumapatients is gaining popularity. However, hemolysis might occur among non-group O recipients. This study evaluated the serologic safety of transfusing up to 4 units of LTOWB. STUDY DESIGN AND METHODS: Hypotensive male and at least 50-year-old female traumapatients who received leukoreduced, uncrossmatched, group O+, low-titer (<50 anti-A and anti-B), platelet-replete whole blood during initial resuscitation were included in this prospective, observational study. Biochemical markers of hemolysis were measured on the day of LTOWB receipt (Day 0) and over the next 2 days. Blood product administration in the first 24 hours of admission and reported transfusion-associated adverse events were also reviewed. RESULTS: There were 102 non-group O and 70 group O recipients of 1 to 4 LTOWB units analyzed. The non-group O recipients received a median volume of 600 mL (range, 300-4100 mL) of ABO-incompatible plasma, including the contribution from the LTOWB units. There were no significant differences in median haptoglobin, lactate dehydrogenase, total bilirubin, creatinine, or potassium levels at any time point between the non-group O and group O recipients. There were also no differences in these markers between the subset of 23 non-group O and 14 group O recipients who received 3 or 4 LTOWB units. No transfusion-associated adverse events were reported. CONCLUSIONS: Administration of up to 4 units of LTOWB in civilian trauma resuscitation was not associated with clinical or biochemical evidence of hemolysis. Six units per traumapatient are now permitted at these institutions.
Authors: Gregory R Stettler; Ernest E Moore; Geoffrey R Nunns; Marguerite Kelher; Anirban Banerjee; Christopher C Silliman Journal: J Surg Res Date: 2020-12-02 Impact factor: 2.192
Authors: Dan Levin; Maoz Zur; Eilat Shinar; Tzadok Moshe; Avishai M Tsur; Roy Nadler; Mark H Yazer; Danny Epstein; Guy Avital; Shaul Gelikas; Elon Glassberg; Avi Benov; Jacob Chen Journal: Transfus Med Hemother Date: 2021-10-06 Impact factor: 3.747
Authors: Frank X Guyette; Mazen Zenati; Darrell J Triulzi; Mark H Yazer; Hunter Skroczky; Barbara J Early; Peter W Adams; Joshua B Brown; Louis Alarcon; Matthew D Neal; Raquel M Forsythe; Brian S Zuckerbraun; Andrew B Peitzman; Timothy R Billiar; Jason L Sperry Journal: J Trauma Acute Care Surg Date: 2022-01-25 Impact factor: 3.697
Authors: Kasiemobi E Pulliam; Bernadin Joseph; Rosalie A Veile; Lou Ann Friend; Amy T Makley; Charles C Caldwell; Alex B Lentsch; Michael D Goodman; Timothy A Pritts Journal: Shock Date: 2021-04-01 Impact factor: 3.533
Authors: Benjamin E Zusman; C Edward Dixon; Ruchira M Jha; Vincent A Vagni; Jeremy J Henchir; Shaun W Carlson; Keri L Janesko-Feldman; Zachary S Bailey; Deborah A Shear; Janice S Gilsdorf; Patrick M Kochanek Journal: J Neurotrauma Date: 2021-09-15 Impact factor: 4.869
Authors: Benjamin E Zusman; Patrick M Kochanek; Zachary S Bailey; Lai Yee Leung; Vincent A Vagni; David O Okonkwo; Ava M Puccio; Lori A Shutter; Keri L Janesko-Feldman; Janice S Gilsdorf; Deborah A Shear; Ruchira M Jha Journal: Neurocrit Care Date: 2020-09-04 Impact factor: 3.532